Christopher Ryan Kelsey

Clinical trials that are currently open include a study of accelerated radiation therapy for locally-advanced thoracic malignancies (non-small cell lung cancer, small cell lung cancer, and inoperable thymic malignancies) in which patients are treated 6 times a week instead of 5 (two treatments on Fridays), using intensity modulated radiation therapy, with the goal of better tumor control with a lower risk of side effects. We also have a study open investigating lower doses of radiation therapy for patients with diffuse large B-cell lymphoma, with the goal of maintaining excellent tumor control but decreasing the risk of long-term side effects of treatment. 

I also have an interest in genetic determinants of radiation sensitivity, predictors of local recurrence after surgery for lung cancer, radiation-induced lung injury, and the role of radiation therapy in advanced (stage III-IV) diffuse large B-cell lymphoma and Hodgkin lymphoma